Regulatory FDA delays decision on Sanofi’s subcutaneous Sarclisa PharmaphorumThe FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.RegulatoryOncologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex. RegulatoryOncologyRead full story Post navigation Previous: MSD-backed Ray locks in $125m to back eye drug pipelineNext: Lilly exits Rigel alliance, adding to RIPK1 scrap heap Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
